Click a topic below for an index of articles:





Financial or Socio-Economic Issues


Health Insurance



Institutional Issues

International Reports

Legal Concerns

Math Models or Methods to Predict Trends

Medical Issues

Our Sponsors

Occupational Concerns

Our Board

Religion and infectious diseases

State Governments

Stigma or Discrimination Issues

If you would like to submit an article to this website, email us at for a review of this paper


any words all words
Results per page:

“The only thing necessary for these diseases to the triumph is for good people and governments to do nothing.”


HIV Fears Prompt Recall of Product for Burn Victims

                        Baxter International Inc. on Monday said it has recalled one lot of a

                        product that hospitals use to treat burn victims and patients in shock

                        after a test found a rare form of HIV in the plasma used to make the


                        ``This is being recalled for quality reasons, not safety reasons,'' said

                        Tanya Tyska, a spokeswoman for the Deerfield, Illinois-based health care

                        products company.

                        Tyska said subsequent evaluation using an experimental test for HIV-2

                        detected low levels of the virus in the plasma pool used to make the

                        product. HIV-2 is rare in the United States.

                        Baxter's voluntary recall of the product, known as Albumin Buminate 5

                        percent, was posted on Friday on the Web site of the US Food and Drug

                        Administration (FDA).


                        During processing, Albumin Buminate is subjected to viral inactivation

                        pasteurization, a process shown to kill HIV.``The manufacturing process

                        destroys the HIV virus. This recall is being taken as a precautionary

                        measure only,'' Tyska said.

                        She said the product met FDA specifications for release and no adverse

                        events have as yet been reported in association with the lot. She declined

                        to say how much product was contained in the lot, but said the company

                        will replace the recalled product with current inventory.


                        Tyska said the company released the product in February, while later

                        testing with the experimental test was done in the past few weeks. She

                        said the company conducts a complete panel of tests on its products.

                        ``This may be one that we add,'' she said of the test, which is used in

                        other countries but is considered investigational in the United States